---
title: "GARNET trial: clinical activity and safety of dostarlimab"
---

Plus, discover the top 3 drug approvals from the past month

| View in browser Weekly newsletter 2 September 2021 Highlights Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab  Top 5 Future Oncology articles – August 2021 Survey: EGFR-mutated non-small-cell lung cancer    Jade's Picks Panel discussion: how I treat non-metastatic castration-resistant prostate cancer   Top 3 drug approvals in oncology: August 2021  Plain language summary of the results from the DESTINY-Breast01 study    Latest news CHRYSALIS: Phase I study demonstrates anti-tumor activity of amivantamab in METex14-mutated NSCLC  Decipher testing utilized for treatment of early-stage prostate cancer    Kind regards, Jade Parker Senior Editor, Oncology Central Future Medicine Ltd, Unitec House, 2 Albert Place, Finchley Central, London N3 1QB, UK, +44 (0) 20 8371 6090 Manage preferences Unsubscribe Privacy Policy Terms & Conditions |
| --- |